TRX319
/ Tr1X
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
March 22, 2026
TRX319 is a novel CAR-Tr1 Treg cell therapy with dual targeting of B cells and T cells for the treatment of progressive multiple sclerosis.
(ASGCT 2026)
- No abstract available
CAR T-Cell Therapy • CNS Disorders • Multiple Sclerosis
March 18, 2026
IMPACT-MS: Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
(clinicaltrials.gov)
- P1/2 | N=39 | Recruiting | Sponsor: Tr1X, Inc.
New P1/2 trial • CNS Disorders • Multiple Sclerosis
February 04, 2026
TRX319: A Novel Regulatory T-Cell Therapy with Dual Targeting of B Cells and T Cells in Progressive MS
(ACTRIMS Forum 2026)
- "TRX319 is a novel cell therapy with a dual mechanism of action designed to target both B and T cells in pMS. Preclinical data demonstrate that TRX319 possesses potent CD19-CAR mediated B cell depletion with enhanced persistence compared to effector CD3+ CAR-T cells, while simultaneously suppressing autoreactive CD4+ T cells. A Phase I/2a dose escalation trial of TRX319 for the treatment of primary and secondary pMS is currently recruiting patients."
IO biomarker • CNS Disorders • Hematological Malignancies • Leukemia • Multiple Sclerosis • Solid Tumor • CD4 • IFNG • IL10 • IL22 • MBP • NGFR • TNFA
October 14, 2025
Tr1X Announces FDA Clearance of IND Application for TRX319, a First-in-Class Allogeneic CAR-Tr1 Treg Cell Therapy for Progressive Multiple Sclerosis…
(Yahoo Finance)
- "On track to initiate TRX319 Phase 1/2a dose-escalation trial in early 2026."
IND • New P1/2 trial • Multiple Sclerosis
October 14, 2025
Tr1X Announces…$50 Million in Additional Financing
(Yahoo Finance)
- "...Allowing Tr1X to advance the TRX319 Phase 1/2a study and the ongoing TRX103 Phase 1/2a trial for patients with refractory Crohn’s disease."
Financing • Crohn's disease • Multiple Sclerosis
1 to 5
Of
5
Go to page
1